Brief: Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds
05/12/2023 13:23
Dec 5 (Reuters) - Enveric Biosciences Inc ENVB.O :
* ENVERIC BIOSCIENCES SELECTS DEVELOPMENT CANDIDATES FROM
EVM301
SERIES BASED ON POTENTIAL TO MINIMIZE OR ELIMINATE THE
HALLUCINOGENIC EFFECT OF PSYCHEDELIC-DERIVED COMPOUNDS
* ENVERIC BIOSCIENCES INC - THREE NOVEL NEUROPLASTIC
COMPOUNDS
IDENTIFIED WITH PLANS TO ADVANCE ONE INTO EXPEDITED PRECLINICAL
DEVELOPMENT IN 2024
* ENVERIC:PLANS TO SELECT 1 OF COMPOUNDS FOR PRECLINICAL
DEVELOPMENT EARLY IN 2024 IN ANTICIPATION OF IND APPLICATION FOR
FIRST-IN-HUMAN CLINICAL TRIAL
* ENVERIC BIOSCIENCES - COMMITTED TO PURSUING THOROUGH AND
EXPEDITED PRECLINICAL PROGRAM IN 2024 IN PREPARATION FOR AN IND
APPLICATION
Source text for Eikon: ID:nBw2lXVrxa
Further company coverage: ENVB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enveric Biosciences
See all newsBrief: Enveric Biosciences Announces Positive Results From IND-Enabling ADMET Studies
Enveric Biosciences Q2 net loss widens
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
Brief: Enveric Biosciences Initiates Investigational New Drug (IND)-Enabling Genotoxicity Studies Of Lead Neuroplastogen Candidate EB-003
Brief: Enveric Biosciences Reports Positive Preclinical Results From Phototoxicity Analysis For Lead Neuroplastogen Candidate Eb-003